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Vascular dementia (VaD) is the second commonest cause of dementia. Stroke is the leading
cause of disability in adults in developed countries, the second major cause of dementia
and the third commonest cause of death. Traditional vascular risk factors – diabetes, hyper-
cholesterolaemia, hypertension and smoking – are implicated as risk factors for VaD. The
associations between cholesterol and small vessel disease (SVD), stroke, cognitive impair-
ment and subsequent dementia are complex and as yet not fully understood. Similarly, the
effects of lipids and lipid-lowering therapy on preventing or treating dementia remain un-
clear; the few trials that have assessed lipid-lowering therapy for preventing (two trials) or
treating (four trials) dementia found no evidence to support the use of lipid-lowering ther-
apy for these indications. It is appropriate to treat those patients with vascular risk factors
that meet criteria for lipid-lowering therapy for the primary and secondary prevention of
cardiovascular and cerebrovascular events, and in line with current guidelines. Managing
the individual patient in a holistic manner according to his or her own vascular risk profile
is recommended. Although the paucity of randomized controlled evidence makes for chal-
lenging clinical decision making, it provides multiple opportunities for on-going and future
research, as discussed here.
Introduction
Dementia is a progressive and largely irreversible clinical syndrome comprising global impairment of
mental function, which manifests as difficulties in memory, language, activities of daily living, and
psychosocial and psychiatric disturbance [1,2]. As of 2015, there were an estimated 46.8million people liv-
ing with dementia worldwide; this number is predicted to double every 20 years, and reach 131.5 million
in 2050 [3].
The three most common dementia subtypes are Alzheimer’s disease (AD), vascular dementia (VaD)
and mixed dementia (combined AD and VaD pathology) [2]. AD is the most common accounting for 60
to 70% of all cases, with a prevalence of approximately 1% in those aged 60–64 years, increasing to 40%
in those aged 85 years or older [4]. VaD accounts for a further 17–25% of cases, [2,4] with an estimated
prevalence of 1.6% and 1.7% in Europe [5] and China [6] respectively. In reality, many people have mixed
AD/VaD disease.
Stroke is the leading cause of disability in adults in developed countries, the second major cause of de-
mentia and the third commonest cause of death [7]. Post-stroke dementia is a major cause of dependency
in stroke survivors and encompasses all dementias after stroke, regardless of aetiology [8]. Traditional vas-
cular risk factors – diabetes, hypercholesterolaemia, hypertension and smoking – are implicated as risk
factors for VaD [9–11], but are also important in ADwith an estimated one third of AD due to modifiable
vascular risk factors [12]. In light of increasing life expectancy, there is an urgent need to find therapies to
prevent and treat both cognitive impairment and dementia.
Here, we review the associations between hypercholesterolaemia and VaD, intracerebral haemorrhage
(ICH) and post-stroke dementia, the effects of statin therapy on stroke, cognitive impairment and demen-
tia, and on-going and future research opportunities.
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Aetiology of vascular dementia
The aetiology of VaD comprises small and large vessel disease. Cerebral small vessel disease (SVD) is the commonest
cause of VaD responsible for 350,000 cases of dementia per year in the U.K. It is characterized by damage to deep
grey and white matter as a result of injury to perforating arterioles and capillaries, although the significance of venu-
lar damage is unclear [13]. Histologically, plasma constituents and inflammatory cells infiltrate arteriolar walls and
perivascular tissue with resultant damage labelled as arteriosclerosis, fibrinoid necrosis and lipohyalinosis [14]. Such
endothelial dysfunction leads to breakdown of the blood–brain barrier (BBB). In addition, perivascular inflamma-
tion is a common pathological feature [15]; blood markers of endothelial activation and inflammation are raised in
lacunar stroke [16]; and cerebral vasoreactivity is impaired [17]. This combination of endothelial dysfunction and
inflammation leads to arteriolar wall thickening, limiting the ability of arterioles to dilate when required [17]. Brain
tissue supplied by stiff and thickened arterioles may be at increased risk of ischaemia and damaged arteriolar walls
may be more likely to precipitate secondary thrombosis [14]. These pathological changes manifest as imaging ab-
normalities that can be detected on magnetic resonance imaging (MRI): lacunar or subcortical infarctions; lacunes;
microbleeds; and white matter hyperintensities (WMH) [18,19]. SVD can present clinically in a number of ways:
lacunar ischaemic stroke (IS); vascular cognitive impairment and VaD; ICH; depression; or gait and/or bladder dys-
function [14]. However, most imaging features of SVD develop silently and when numerous lacunes, microbleeds
and/or WMH are present there is an increased risk of cognitive impairment, dementia and stroke [20–22]. In con-
trast, other causes of stroke such as large vessel disease – extracranial or intracranial – and cardioembolic disease [e.g.
atrial fibrillation (AF), recent myocardial infarction (MI)] have differing pathological mechanisms to SVD; athero-
sclerosis and enhanced platelet function in large artery stroke and pro-coagulant activity in cardioembolic disease
[22].
Several factors are implicated in the development of post-stroke dementia. These can be split into demographic
and clinical characteristics, stroke characteristics and neuroimaging findings (Table 1) [8]. Attempting to determine
the degree of cognitive impairment that can be attributed to either stroke, concurrent AD or SVD remains difficult.
The proportion of patients with post-stroke dementia presumed to have AD varies widely from 19% to 61% [23].
Of those with post-stroke dementia approximately one third have medial temporal atrophy, [24] and 15–30% have a
diagnosis of dementia that predates their stroke [24,25]. These two factors may increase the likelihood of AD in this
group of patients, but this is speculative at present [26].
Intracerebral haemorrhage and vascular dementia
Although ICH accounts for only 15% of strokes, it is associated with high rates of stroke-related death and disability
[27,28]. Re-bleeding, IS and cognitive impairment and dementia – all frequent events following ICH – are endpoints
thatmay bemediated by underlying SVD,which is probably the aetiology responsible for these secondary clinical out-
comes and ICH [14,29]. Indeed, compared with general elderly controls those with ICH have an increased frequency
of both neuroimaging and genetic markers of SVD [30–32].
Despite dementia being common after ICH, its risk factors are poorly understood. One recent study sought to es-
tablish whether different factors were associated with early (!6 months) or delayed (>6 months) dementia following
ICH [33]. Dementia diagnosis was based on International Classification ofDiseases-9 (ICD-9) codes established from
electronicmedical records and/ormodified Telephone Interview forCognitive Status (TICS-m) scores<20. The sens-
itivity and specificity of dementia diagnoses established from ICD-9 codes and TICS-m compared with face-to-face
assessment by a neurologist (available in 70.7% of the cohort) were 90% and 94% respectively. Of the 738 people with
ICH recruited, 279 (37.8%) developed dementia during themedian follow-up of 47.4 months; 140 patients developed
dementia within 6 months, with the remaining 139 being diagnosed more than 6 months post-ICH. Risk factors for
early and delayed dementia after ICH varied significantly [33]. ICH volume, lobar location and presence of"1 copy
of apolipoprotein E (APOE) ε2 were associated with early dementia but not delayed dementia. The APOE ε2 variant
has been reported to be associated with larger haematoma volumes and/or expansion and therefore poor functional
outcome at 90 days [34,35]. Conversely, educational level, pre-morbid mood disturbance, imaging markers of SVD
[white matter disease on computed tomography (CT) and cerebral microbleeds (CMB)] and presence of "1 copy of
APOE ε4 were associated with delayed but not early dementia [33].
Biffi et al. [33] report a high incidence of dementia (5.8% per year), which could be an overestimation, perhaps
through the use of TICS-m rather than in-person assessment, although the concordance between telephone and
in-person assessments was high. Despite this, it is clear that cognitive impairment or dementia following ICH is
under-recognized. In summary, ICH characteristics were associated with early and not late dementia after ICH, and
markers associated with both SVD and late-onset AD were associated with delayed onset dementia [33]. Further
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Table 1 Predictors of post-stroke dementia [8,26]
ACA, anterior cerebral artery; CCF, congestive cardiac failure; PCA,
posterior cerebral artery.
Clinical/demographic predictors
Increasing age
Low education level
Pre-stroke dependency
Pre-stroke cognitive decline without dementia
Hypertension
DM
AF
MI
Epileptic seizures
Sepsis
Cardiac arrhythmias
CCF
Stroke predictors
Severe neurological deficit at stroke onset
Stroke recurrence
Supratentorial stroke
Left hemisphere stroke
ACA and PCA territorial infarcts
Strategic infarcts:
Left angular gyrus
Inferomedial temporal
Mesial frontal
Anterior and dorsomedial thalamus
Left capsular genu
Caudate nucleus
Multiple infarcts
Increased volume of stroke lesion [195]
Early post-stroke complications [196]
Seizure
Delirium
Hypoxia
Hypotension
Neuroimaging predictors
Silent infarcts
Global cerebral atrophy
Medial temporal lobe atrophy
White matter changes
studies are required to elucidate the contribution of AD to cognitive impairment following ICH. Although this cohort
provides evidence of separate risk factors for early and late dementia after ICH, these results need to be verified.
An important question to address in those with delayed dementia following ICH is whether cognitive impairment
is secondary to the ICH, or are the bleed and cognitive impairment both sequelae of the same underlying disease
process [36]?
Lipid effects on vascular dementia
There are a variety of pathological mechanisms involved in the development of VaD, and lipids have a vital role in
many of these processes. Both high levels of low-density lipoprotein (LDL) cholesterol and low levels of high-density
lipoprotein (HDL) cholesterol are known risk factors for carotid atherosclerosis and coronary artery disease [37,38],
which may result in cognitive impairment secondary to cerebral hypoperfusion or embolism [39]. HDL cholesterol
c⃝ 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
1563
Clinical Science (2017) 131 1561–1578
DOI: 10.1042/CS20160382
may be involved in the removal of excess cholesterol from the brain mediated by APOE and heparin sulphate pro-
teoglycans in the subendothelial space of cerebral microvessels [40]. In addition, HDL particles reverse the inhibitory
action of oxidized LDL particles on endothelium-dependent arterial relaxation [41] and also inhibit cytokine-induced
expression of endothelial cell adhesion molecules [42]; both of which may be potential mechanisms in the develop-
ment of VaD.
Oxidative stress and lipid oxidation in particular have a pivotal role in the development of VaD [43]; lipid peroxid-
ation may influence neuronal membrane permeability, affecting cellular function and damaging membrane-bound
receptors and enzymes [44]. The brain may be particularly susceptible to oxidative lipid damage due to its high con-
tent of polyunsaturated fatty acids [44]. Paraoxonase 1 is an A-esterase with peroxidase-like activity present on the
surface of HDL, which decreases peroxidation of LDL. Levels of paraoxonase 1 decrease with increasing age and in
those with cardiovascular disease (CVD); they have also been found to be reduced in patients with VaD [45]. Further
evidence for the role of oxidative stress comes from the demonstration of low levels of plasma antioxidants in patients
with AD and VaD compared with controls; vitamins A, C and E, uric acid and carotenoids were all significantly lower
than controls [46]. However, in the same cohort there was no difference in plasma malondialdehyde, a biomarker of
lipid peroxidation, between controls and those with either AD or VaD [46]. Low plasma vitamin E levels have also
been seen in patients with VaD in comparison with controls, although in a published cohort levels in people with AD
were similar to controls [47]. Low levels of antioxidants may render individuals more susceptible to oxidative stress
and thus reduced antioxidant defences may have an important role in the development of VaD.
Apolipoprotein B (ApoB) is themain surface protein found on pro-atherogenic lipoproteins: LDL; very-low density
lipoprotein (VLDL); intermediate density lipoprotein (IDL); and lipoprotein (a) [48]. One particle of pro-atherogenic
lipoprotein contains onemolecule of ApoB [49], thus ApoB provides a surrogatemeasure of the number of circulating
pro-atherogenic lipoprotein particles. As such, ApoB may be more strongly related to cardiovascular risk than cho-
lesterol contained within the lipoproteins. However, epidemiological data are inconclusive and therefore discrepancy
exists between current guidelines on the significance of ApoB to cardiovascular risk [50–52]. Data on ApoB and SVD
or dementia are scanty. A Swedish twin study (n=60) found that higher ApoB at baseline predicted dementia at least
3 years later, although any cause of dementia was included in this small study [53]. A pooled analysis of two Finnish
prospective population-based cohort studies (n=13,275) found that baseline ApoB was not associated with incident
AD or dementia 10 years later [54]. At present, the role of ApoB in the development of SVD or VaD is unclear.
Whilst several studies have reported no association between LDL cholesterol and MRI markers of SVD [55–57],
one cohort (n=1,919) noted a significant relationship between reducing LDL cholesterol andWMHprogression [58].
Further, in 1,135 acute IS patients hypercholesterolaemia, hypertriglyceridaemia or use of lipid-lowering medication
was associated with decreased WMH severity [59]. Unfortunately, the authors were unable to assess the contribu-
tion of statin therapy to the association seen, which may have confounded their findings. Although a smaller cohort
(n=112) found no association between midlife total cholesterol and WMH two decades later, lipid-lowering ther-
apy decreased the risk of WMH being present in later life [60]. Lower midlife HDL cholesterol was associated with
increased WMH volumes in later life in 148 monozygotic male twins [61]. The somewhat contradictory findings re-
garding the associations between cholesterol andWMH are also noted in regard to lacunes. A cross-sectional analysis
of MRI data (n=1,827) found that smaller lacunes (!7 mm) were associated with diabetes mellitus (DM) and larger
lacunes (8–20 mm) were associated with LDL cholesterol [62]. The authors propose that these differences support
the theory that differing pathologies result in small and large lacunes, namely lipohyalinosis and microatheroma re-
spectively [62]. Within the Leukoaraiosis and Disability study (n=396) lower HDL cholesterol was associated with
new lacunes on MRI over 3 years, whilst high LDL cholesterol was protective against formation of new lacunes [55].
In contrast, the Rotterdam Scan Study (n=668) found no association between total HDL cholesterol and incident
lacunar infarcts over 3 years, but did note an association between carotid atherosclerosis and incident lacunar in-
farcts [57]. Although the data are unclear, there may be a suggestion that LDL cholesterol is not as damaging to small
arteries as it is to larger vessels.
Epidemiological data from two French cohorts (n=2,608) found that increasing triglyceride levels, but not LDL
or HDL cholesterol, were associated with larger WMH volume and lacunes on MRI; an effect that was maintained
after adjusting for inflammatory markers and vascular risk factors, and in those taking and not taking lipid-lowering
therapy [63]. There are several proposed mechanisms to explain this association. Firstly, triglyceride levels have been
associated with breakdown of the BBB, contributing to the formation of lacunes [55] and WMH [64]. Secondly,
triglyceride levels are associatedwithmarkers of inflammation [65], which in turn have been reported to be associated
withMRI features of SVD [66,67]. Thirdly, APOE plays a pivotal role in lipid metabolism and polymorphisms ε2 and
ε4 have been found to be associated with MRI markers of SVD [68]. Finally, triglyceride levels adversely affect the
compliance of small arteries [69], which may potentially contribute to chronic white matter hypoperfusion [70].
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Cholesterol lowering medications, such as statins, are used to prevent first and recurrent vascular events including
MI and IS [71,72]. Reducing stroke occurrence by lowering cholesterol may, as a consequence, reduce the incidence
of post-stroke dementia. The Finnish Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study found that
midlife total cholesterol predicted cognitive impairment 21 years later, an effect that was attenuated following adjust-
ment for statin usage [73]. Similarly, raised midlife cholesterol was associated with an increased risk of developing
VaD over a 30-year period in a study based on medical records [74]. In contrast, results from cohorts involving those
in later-life vary with some finding higher levels of cholesterol to be associated weakly with a higher risk [37], and
others finding a relationship with a lower risk [75] of VaD. These inconsistencies probably represent the timing of
cholesterol measurement in relation to age and clinical onset of dementia. Indeed, pravastatin in older people at risk
of CVD had no effect on multiple cognitive outcomes when compared with placebo [76].
Lipid effects on Alzheimer’s disease
Whilst both coronary heart disease and hypertension are independent risk factors for AD [77,78], the association
between cholesterol and AD is less clear. There are conflicting epidemiological data; some report an association
between raised serum cholesterol levels and an increased risk of developing AD [74,77,79–81], whereas other studies
have shown no effect [82–88] or a negative association [37,75]. These incongruous findings are likely to be due to
differing study design, participant age at enrolment (mid- compared with later-life), timing of cholesterol measure-
ment in terms of age and dementia onset and length of follow-up. APOE is an important protein involved in cerebral
cholesterol transport and influences aggregation and clearance of amyloid-β peptide [89–91]. The amyloid cascade
hypothesis suggests that an imbalance between production and clearance of amyloid-β is the first step in AD patho-
genesis, culminating in neuronal degeneration and dementia [92]. This provides a theoretical link between cholesterol
metabolism and pathogenesis of AD. Presence of the APOE ε4 allele increases the risk of AD by 3 and 15 times in
heterozygotes and homozygotes respectively [93]. The ε4 allele is associated with a higher risk of atherosclerosis and
higher plasma levels of total and LDL cholesterol [94]. In addition, several other genes involved in cholesterol meta-
bolism have been associated with AD including adenosine triphosphate (ATP)-binding cassette subfamily Amember
7 (ABCA7) [95], clusterin [96] and sortilin-related receptor (SORL1) [97].
The majority of cerebral cholesterol is produced locally and is not transported into plasma due to the BBB [98].
Cerebral cholesterol levels are not altered by high LDL or low HDL cholesterol plasma levels, but whether intramem-
branous lipid domains or intracellular cholesterol content are affected remains unclear [99]. Cholesterol removal from
the brain is mediated by 24-hydroxycholesterol [100], which is crucial for cerebral cholesterol homoeostasis [101].
Diet-induced hypercholesterolaemia in animal models has been associated with increased amyloid-β and APOE
levels in temporal and frontal cortical regions, in line with the geographical amyloid-related pathological changes
seen in AD [102].
Ischaemia has been noted to cause up-regulation of amyloid precursor protein expression with resultant amyloid-β
deposition in human brains [103]. Furthermore, co-existent cerebrovascular and amyloid-β plaque pathology may
increase the chance of clinically apparent dementia occurring [104].
Epidemiology of lipids and intracerebral haemorrhage
The association between higher total and LDL cholesterol levels and increased IS risk is seen in most observational
studies [105–116]. Similarly, most observational data report an association between lower total and LDL cholesterol
levels and increased ICH risk (Table 2) [106,117–121]. A meta-analysis of 23 prospective studies involving 1,430,141
patients found an association between lower total cholesterol and increased rates of ICH; dose–response analysis
revealed a relative risk (RR) of ICH per 1 mmol/l increment of total cholesterol of 0.85 (95% confidence interval [CI]
0.80–0.91) [122]. The nature of this association remains poorly understood. Of note, low levels of LDL cholesterol
have been identified in patients with haematological cancers [123] and liver disease [124], who have a higher risk of
ICH.
Studies assessing triglycerides and stroke risk have shown similar results to total cholesterol (Table 2): for each
0.1 mmol/l increase in baseline triglycerides, there was an associated RR of IS of 1.05 (95% CI 1.03–1.07) [125];
triglyceride levels were also inversely associated with ICH [120,121].
Statins
Statins are 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. This enzyme is involved in
cholesterol synthesis and by inhibiting its activity statins reduce formation and release of LDL cholesterol, up-regulate
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Table 2 Lipids and ICH
CV, cardiovascular.
Lipid Study n Results Comments
Total cholesterol Multiple risk factor
Intervention Trial
[117]
350,977 men (U.S.A.) Risk of death from ICH
was three times higher
in men with cholesterol
<4.14 mmol/l,
compared with high
levels
Risk of death from ICH
when cholesterol
<4.14 mmol/l was
overwhelmed by the
positive association of
higher cholesterol with
death from IS and total
CV disease
Korean Medical
Insurance
Corporation Study
[118]
114,793 men (Korea) Low total cholesterol was
not an independent risk
factor for ICH
This cohort had a mean
age of 45.4 years and
were government
employees with stable
socioeconomic status,
not necessarily
representative of
middle-aged Korean
men
Asia Pacific Cohort
Studies
Collaboration [106]
352,033
(Asia/Australasia)
Each 1 mmol/l increase in
total cholesterol was
associated with 20%
decreased risk of fatal
ICH
Each 1 mmol/l increase in
total cholesterol was
also associated with
35% increased risk of
coronary death, 25%
increased risk of IS
LDL cholesterol Pooled analysis of the
ARIC study and
Cardiovascular
Health Study [119]
21,680 (U.S.A.) LDL cholesterol was
inversely associated
with ICH [RR of ICH for
top quartile versus
quartiles 1–3: 0.52
(95% CI 0.31–0.88)]
Total cholesterol and HDL
cholesterol levels were
not associated with
ICH
Triglycerides Pooled analysis of the
ARIC study and
Cardiovascular
Health Study [119]
21,680 (U.S.A.) Triglycerides were
inversely associated
with ICH [RR of ICH
per log unit mg/dl: 0.56
(95% CI 0.37–0.84)]
Total cholesterol and HDL
cholesterol levels were
not associated with
ICH
Three City Study [120] 8,393 (France) A low triglyceride level
(!0.94 mmol/l) was
associated with an
increased risk of ICH
(HR 2.36, 95% CI
1.18–4.70)
A high triglyceride level
("1.34 mmol/l) was
associated with an
increased risk of
ischaemic events,
coronary events and IS
Rotterdam Study [121] 9,068 (Netherlands) Triglycerides were
inversely associated
with ICH (HR for
highest versus lowest
quartile: 0.20 (95% CI
0.06–0.69)
A similar association was
seen between
triglycerides and CMBs
in deep or infratentorial
regions; no
associations for LDL or
HDL cholesterol were
found
LDL receptor activity [126], with subsequent lowering of LDL cholesterol and triglycerides, and increase in HDL
cholesterol [127]. In addition to their effects on lipids, statins increase the integrity of the BBB, improve endothelial
cell function [128] and reduce platelet aggregation, smooth muscle cell proliferation and markers of inflammation
[e.g. C-reactive protein (CRP)] [129,130]. Statins can be classified according to whether they are soluble in water
(hydrophilic) or in lipids (lipophilic). Atorvastatin, fluvastatin, lovastatin and simvastatin are lipophilic statins and
therefore cross the BBB and cell membranes with greater ease than their hydrophilic equivalents (pravastatin) [131].
Statin therapy protects against stroke in terms of both primary and secondary prevention. In the Heart Protection
Study (HPS), involving 20,536 participants aged 70–80 years at high risk of vascular disease, simvastatin (40 mg daily)
was associated with a 20% reduction in stroke risk compared with placebo [132]. Atorvastatin 80 mg versus 10 mg
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daily was associated with a 25% reduction in stroke risk in the Treating to New Targets (TNT) study [133]. Two large
meta-analyses have shown significant reductions in stroke risk for each 1 mmol/l reduction in LDL cholesterol with
statin therapy; 21.1% [134] and 16% [135] RR reduction respectively.
In those with a history of cerebrovascular disease in HPS (n=3,280), simvastatin was associated with a 20% re-
duction in major cardiovascular events compared with placebo, but there was no reduction in stroke rate [132]. The
Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial (n=4,742) found that atorvastatin
(80 mg) was associated with an RR reduction in recurrent stroke of 16% compared with placebo [136]. These results
were seen in both subgroups with large artery stroke and lacunar stroke, and in those with transient ischaemic attack
(TIA).
Statins in ICH
Epidemiological evidence described above suggests that there is an inverse association between lipids and ICH. Fur-
ther studies assessing the relationship between statin usage and ICH have had conflicting results. The HPS showed a
non-significant increased risk of ICH in those randomized to simvastatin compared with placebo [132], whilst those
participants treated with atorvastatin in the SPARCL trial had an higher risk of ICH than those who received placebo
[136]. Retrospective analysis using the Virtual International Stroke Trials Archive (VISTA) dataset (n=8,535) com-
pared participants with prior statin usage and recently commenced statin within 3 days of acute IS with those without
statin exposure. There was no association between statin use and early symptomatic ICH or any ICH, regardless of
whether thrombolysis was administered or not. Indeed, there was a non-significant tendency to less death at 90 days
in participants with prior statin usage (adjusted hazard ratio [HR] 0.84, 95% CI 0.70–1.00) and recently commenced
statin therapy (adjusted HR 0.67, 95% CI 0.46–0.97) [137]. Meta-analysis of 31 trials revealed no increased risk of
ICH in people taking statins (odds ratio [OR] 1.08, 95% CI 0.88–1.32) [138].
Statins in VaD
Trials of statins assessing outcomes relevant to cognition, dementia and SVD are lacking. Several observational stud-
ies have observed an association between statin use and dementia. These have been systematically reviewed by sev-
eral groups of authors. All found significant heterogeneity between studies and reported the biases and confounding
factors commonly associated with observational research, making conclusive results and implications for practice
difficult to establish and disseminate [139–141]. The key confounders can be summarized as follows. First, inclusion
of those with advanced dementia or very elderly people, who carry multiple vascular risk factors and are therefore at
risk of vascular disease. Second, differentmarkers of dementia were used including a variety of cognitive tests and dia-
gnostic definitions. Third, different statin types were assessed including lipophilic and hydrophilic subtypes. Fourth,
the duration of treatment and timing of assessment in relation to the former varied considerably. Fifth, patients from
lower socioeconomic class are less likely to be prescribed statins. Last, the pathophysiology of VaD is heterogeneous
with significant overlap with AD [142].
Two randomized controlled trials (RCTs) of statins have reported outcomes relating to cognition. The aforemen-
tioned HPS showed that simvastatin had no effect on cognitive decline, evaluated using TICS-m, compared with
control [132]. A less potent statin (pravastatin) was assessed in the Prospective Study of Pravastatin in the Elderly
at Risk (PROSPER) study and exerted no effect on cognitive function, measured by mini-mental state examination
(MMSE), after 4 years of treatment (n=5,804) in those aged 70–82 years at baseline [76]. A subsequentmeta-analysis,
under the auspices of the Cochrane Collaboration, of these two trials did not alter the neutral effects seen within the
trials individually (Table 3) [4]. Similarly, assessment of pravastatin and simvastatin on WMH progression in the
PROSPER (n=535) and Regression of Cerebral Artery Stenosis (ROCAS) (n=227) studies respectively found neut-
ral effects [143,144]. In summary, evidence to date suggests that statins given in later life have no effect on preventing
cognitive decline or dementia [4,26]. The American Heart Association guideline suggests that treatment of hyper-
cholesterolaemia for prevention of dementia has uncertain usefulness [26].
The Prevention Of Decline in Cognition After Stroke Trial (PODCAST) [145] randomized patients without de-
mentia who were 3 to 7 months after stroke to intensive (systolic <125 mmHg) versus guideline (systolic <140
mmHg) blood pressure lowering. In addition, participants with IS were randomized to intensive (<1.3 mmol/l)
versus guideline (<3 mmol/l) lipid-lowering therapy. Lipid-lowering therapy was suggested to investigators as fol-
lows: guideline to simvastatin 10–40 mg, pravastatin 10–40 mg or fluvastatin 10–80 mg; intensive to atorvastatin
>20 mg or rosuvastatin at any dose. Eighty-three participants were recruited and followed-up for a median of 24
months. Although total and LDL-cholesterol were reduced with intensive versus guideline lipid-lowering therapy,
there was no difference in the Addenbrooke’s Cognitive Examination-Revised (ACE-R, primary outcome) between
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Table 3 Summary of systematic reviews with meta-analyses for lipid-lowering therapies
MD, mean difference; SMD, standardized mean difference.
Intervention Population Trials Patients
Stroke RR/OR
(95% CI)
Cognitive
impairment MD/OR
(95% CI) ICH
Statins for
dementia
prevention [4]
Normal cognition 1 20,536 OR 1.0 (0.61, 1.65)
1 5,804 MD MMSE 0.06
(−0.04, 0.16)
Statins for
dementia
treatment
[131]
Probable or
possible AD
4 1,110 ADAS-Cog MD − 0.26
(−1.05, 0.52)
4 1,127 MMSE MD − 0.32
(−0.71, 0.06)
Statins [164] Normal cognition 14 27,643 SMD 0.01 (−0.01,
0.03)
AD 4 935 SMD −0.05 (−0.19,
0.10)
Statins [138] ICH 31 182,803 OR 0.84 (0.78,
0.91)
OR 1.08 (0.88,
1.32)
Statins [155] AD 3 546 MMSE MD 1.14
(−0.20, 2.47)
Niacin [166] CVD 11 9,959 OR 0.88 (0.50,
1.54)
Diet [177] CVD 7 60,554 OR 0.92 (0.69,
1.23)
Fibrates [177] CVD 12 28,144 OR 0.98 (0.86,
1.12)
Fibrates [168] CVD 18 45,058 RR 1.03 (0.91,
1.16)
PCSK-9
inhibitors [176]
Hyperlipidaemia 2 4,465 RR 1.43 (0.45,
4.57)
groups during treatment. However, intensive lipid-lowering was associated with improvements in several secondary
outcomes including cognition (ACE-R at 6 months, trail making A), death or dependency (modified Rankin Scale;
mRS) and quality of life (Euro-QoL visual analogue scale). Unfortunately, PODCAST grossly under-recruited com-
pared with an initial protocol target of 600 participants [146], and was therefore underpowered for all outcomes. In
a post hoc global analysis of multiple outcomes (using theWei–Lachin test [147]), intensive lipid lowering improved
on-treatment global cognition (Figure 1) and on-treatment global outcome (Figure 2), findings that warrant further
investigation.
Data regarding statins as treatment for established dementia (either AD or VaD) are limited. Observational data
from one study that followed patients with AD for 35 months suggested that people treated with lipid-lowering ther-
apy had a slower decline in MMSE scores than those with untreated hyper- or normo-cholesterolaemia [148]. In
the Ginkgo Evaluation of Memory Study, those without mild cognitive impairment at baseline who were on statins
had a reduced risk of both AD (HR 0.57, 95% CI 0.39–0.85) and overall dementia (HR 0.79, 95% CI 0.65–0.96).
In contrast, those with mild cognitive impairment at baseline on lipid-lowering therapy (including statins) had no
evidence of cognitive benefit [149]. Further, a pooled analysis involving data from three RCTs of galantamine in AD
found no change in cognition associated with the use of statins [150]. A recent Cochrane review found no RCTs
that have assessed statins in the treatment of VaD, but identified four that assessed these medications (atorvastatin
and simvastatin in two studies each) in AD (Table 3) [131]. These four studies [151–154] involved 1,154 participants
aged 50–90 years with diagnoses of probable or possible AD. The authors found no change in the primary outcome
of Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) from baseline in those who received stat-
ins compared with those on placebo. Equally, there was no significant difference in MMSE scores from baseline
between those randomized to statins compared with placebo [131]. These findings echo previous results prior to the
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On-treatment cognition
ACE-r
MMSE
MoCA
TICS-m
Trail making B: time
Trail making B: correct answers
IQ code
Animal naming
Stroop interference: accuracy
Stroop interference: time
Combined Wei-Lachin
N
74
74
74
74
74
74
74
74
72
72
77
P-value
0.059
0.13
0.071
0.25
0.34
0.1
0.13
0.013
0.04
0.32
0.023
-0.6 -0.4 -0.2 0 0.2 0.4 0.6
Favours Guideline            Favours Intensive
Figure 1. On-treatment global cognition: data from PODCAST
Analyses were performed using the multivariate directional Wilcoxon test. The effect sizes are the Mann–Whitney difference (and 95% CI)
for each of the individual outcomes and for the combined outcome (using the Wei–Lachin procedure).
On-treatment outcome
mRS
Barthel index
EQ-5D HUS
Zung depression scale
Telephone MMSE
Combined Wei-Lachin
N
74
74
73
73
73
77
P-value
0.11
0.0091
0.16
0.55
0.03
0.023
-0.6 -0.4 -0.2 0 0.2 0.4 0.6
Favours Guideline          Favours Intensive
Figure 2. On-treatment global outcome: data from PODCAST
Analyses were performed using the multivariate directional Wilcoxon test. The effect sizes are the Mann–Whitney difference (and 95% CI)
for each of the individual outcomes and for the combined outcome (using the Wei–Lachin procedure); EQ-5D HUS, Health utility status
derived from Euro-quality of life five dimensions.
publication of Sano et al. [153] in which neither a treatment effect nor a difference between trials of atorvastatin and
simvastatin was seen [155]. There is, therefore, no evidence to recommend the use of statin therapy for the treatment
of AD or VaD. Despite this, a proportion of clinicians choose to prescribe statins for both primary and secondary
prevention of vascular cognitive impairment [156].
Statin-induced cognitive impairment
There has been significant interest in the suggestion that statin treatmentmaynegatively affect cognition. Randomized
trials, case reports, observational studies and post-marketing surveillance have all reported data regarding cognitive
impairment in people taking statins [149,157–161]. Symptoms of confusion, forgetfulness andmemory loss have been
reported within a few days of starting therapy, whilst others report symptom-onset years after commencing statins.
Overall, the symptoms were not serious and reversed within a few weeks of ceasing statin therapy. Subsequently, at
least three groups have systematically appraised the situation and found that there is no significant evidence to suggest
that statins cause cognitive impairment [162–164]. For example, the meta-analysis by Ott et al. [164] involved 14
c⃝ 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
1569
Clinical Science (2017) 131 1561–1578
DOI: 10.1042/CS20160382
RCTs (n=27,643) and found that statins were not associated with cognitive impairment in either cognitively normal
participants or people with AD (Table 3) [164].
Other lipid-lowering therapies and VaD
Alternative lipid-lowering agents are (at present) less efficacious at primary or secondary stroke prevention than
statins [165]. Despite niacin increasing levels of HDL cholesterol, a systematic review and meta-regression including
11 studies with 9,959 patients showed no significant improvement in stroke risk (OR 0.88, 95% CI 0.50–1.54, Table 3)
[166]. Similarly fibrates increase HDL cholesterol, but also lower triglyceride levels. In the Veterans Affairs-HDL
Intervention Trial (VA-HIT), gemfibrozil reduced stroke risk by 31% in men with low HDL cholesterol and coronary
artery disease [167]. Meta-analysis of 18 trials totalling>45,000 patients found that fibrates had no significant effect
on stroke risk [168]. Observational data fromCanada (n=2,305) suggested that use of statins and other lipid-lowering
agents in those aged less than 80 years reduced the risk of overall dementia and, in particular, AD [169]. Alternative
data from an U.K. general practice cohort found that individuals prescribed statins had a significantly reduced risk
of developing dementia; an effect not demonstrated with other lipid-lowering treatments [170].
Ezetimibe reduces total cholesterol levels by inhibiting intestinal cholesterol absorption. When added to simvast-
atin (40 mg daily), ezetimibe (10 mg daily) significantly reduced stroke risk (HR 0.86, 95% CI 0.73–1.00, p= 0.05)
comparedwith simvastatinmonotherapy over amedian follow-up of 6 years after acute coronary syndrome in the Im-
proved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT, n=18,144) [171]. This reduced
stroke risk was driven by a reduction in IS events (HR 0.79, 95% CI 0.67–0.94) between the two groups described. To
date, no trials have specifically assessed ezetimibe in the prevention or treatment of dementia.
Proprotein convertase subtilisin-kexin type 9 (PCSK-9) inhibitors are parenterally administered, monoclonal anti-
bodies that lower LDL cholesterol levels by preventing degradation of hepatic LDL receptors. When added to statins,
PCSK-9 inhibitors reduce LDL cholesterol by 40–72% [172]. A meta-analysis of 24 studies including 10,159 parti-
cipants found that PCSK-9 inhibitors were associated with reductions in all-cause mortality, cardiovascular mortality
and the rate of MI compared with placebo [173]. The OSLER 1 and 2 studies (n=4,465) reported that the risk of ma-
jor cardiovascular events (including stroke and TIA), over a median of 11 months follow-up, was reduced by 53% in
those who received evolocumab [174], whilst in the ODYSSEY LONG TERM study (n=2,341) the rate of first major
cardiovascular events (including IS), over a median follow-up of 18 months was lower (HR 0.52, 95% CI 0.31–0.90)
with alirocumab compared with placebo [175]. A recent meta-analysis of these two trials sought to establish the effect
of PCSK-9 inhibitors on stroke risk, but was limited due to the small number of strokes reported over relatively short
follow-up periods: 5 ISs and 6 TIAs in OSLER, and 11 ISs in ODYSSEY LONG TERM [176]. There was no difference
in stroke rates between PCSK-9 inhibitors and placebo (risk ratio 1.43, 95% CI 0.45–4.57). Further data are needed
over longer follow-up duration to establish the efficacy of PCSK-9 inhibitors at reducing incident strokes.
Although there is no evidence regarding PCSK-9 inhibitors and prevention or treatment of dementia, there have
been reports of increased neurocognitive adverse events (confusion, memory problems) with these agents compared
with placebo [176]. Clearly, further research andmonitoring are required before these agents can be used in the setting
of primary or secondary prevention of stroke or dementia.
In summary, a large meta-analysis of 78 trials (n=266,973) of lipid-lowering therapy found no significant effect of
non-statin lipid-lowering on stroke risk (diet: OR 0.92, 95% CI 0.69–1.23; fibrates: OR 0.98, 95% CI 0.86–1.12; other
drugs: OR 0.81, 95% CI 0.61–1.08, Table 3) [177].
Ideal cardiovascular health
As discussed previously, stroke and its recurrence are predictors of dementia [8]. In addition, other vascular diseases
– namely coronary artery disease, peripheral arterial disease, AF, renal disease and cardiac failure – have all been asso-
ciated with cognitive impairment and VaD [26]. Stroke and these other vascular diseases probably represent markers
of cumulative exposure to multiple vascular risk factors. In addition to hypercholesterolaemia, modifiable vascular
risk factors comprise diabetes, hypertension, obesity, physical inactivity and smoking, which are all independently
associated with cognitive impairment and dementia in later life [178–182]. In order to promote cardiovascular health
(CVH) and reduce deaths fromCVDand stroke by 20% by 2020, theAmericanHeart Association developed theCVH
index, a 7-point score ranging from 0 to 7, with one point awarded for each of: current non-smoker; body mass in-
dex (BMI)>18.5 and<25 kg/m2; adequate physical activity; a healthy diet; untreated total cholesterol<5.2 mmol/l;
untreated blood pressure <120/80 mmHg; and fasting blood glucose <5.6 mmol/l [183]. Higher scores indicating
ideal CVH have predicted less coronary artery disease and stroke (IS and ICH) in at least three separate cohorts in
the U.S. [184–186] and one in China [187,188]. One prospective cohort study aimed to assess whether ideal CVH
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Box 1 Unanswered questions for future research regarding hypercholesterolaemia in VaD
FOURIER, Further Cardiovascular OUtcomes Research with PCSK-9 Inhibition in Subjects with Elevated Risk.
Prevention Comment
What is the relationship between dementia onset and
cholesterol level?
As cholesterol level increases is the relationship with
disease onset linear?
Does lowering of ‘normal’ cholesterol levels influence the
timing of dementia onset?
If so, when should this be done – middle age, late age? Is
there an age cut-off above which cholesterol should not
be lowered?
Does (the degree of) lowering of cholesterol levels
influence the severity or progression of dementia in a
pre-symptomatic population?
Does the concept of over excessive cholesterol lowering
exist i.e. can ‘too low’ be detrimental?
Does timing of lipid-lowering therapy influence dementia
onset or severity?
Does treatment started in midlife have a benefit over
starting later in life?
Does targeting ideal CVH in midlife influence
onset/severity of dementia [189]?
Further data are needed. A large RCT could answer this
question but would be potentially prohibitively
expensive.
Treatment of existing dementia
Are statins of benefit in the treatment of VaD? In order to accurately test efficacy, should people with mild
cognitive impairment (at worst) be recruited to future
trials?
Does targeting ideal CVH in an at-risk population in later
life influence severity/progression of dementia?
FINGER showed that a multi-domain intervention can
prevent deterioration in cognitive functioning over
2 years in those in later life [191]. Whether this effect is
maintained, is unclear.
Lipid-lowering therapy
Cholesterol level target versus class of lipid-lowering
therapy
Is target lipid-lowering more or less effective than the
choice of lipid-lowering agent?
Lipophilic versus hydrophilic statins Lipophilic statins can cross the BBB, whilst hydrophilic
statins cannot. Some authors advocate that lipophilic
statins should be assessed above other statins in
preventing/treating dementia due to this property [131].
Are PCSK-9 inhibitors safe and efficacious at reducing
stroke in primary and/or secondary stroke prevention?
Concern surrounds the safety of PCSK-9 inhibitors in this
population given their reported neurocognitive adverse
effects. Although a recent press release stated that
evolocumab was non-inferior to placebo regarding
effects on cognition in a study involving FOURIER
participants [197]. Further monitoring and trials are
required to answer these questions.
was associated with lower risk of stroke, cognitive impairment and dementia in the Framingham Heart Study Off-
spring cohort [189]. The authors assessed whether ideal CVH scores at two time-points – recent (1998–2001) and
remote (1991–1995) – were associated with 10-year risk of stroke (n=2,631), cognitive impairment and dementia
(n=1,364). Higher remote ideal CVH was associated with a lower 10-year risk of incident stroke (HR 0.79, 95% CI
0.66–0.94), AD (HR 0.79, 95% CI 0.64–0.98), VaD (HR 0.61, 95% CI 0.39–0.95) and all-cause dementia (HR 0.80,
95% CI 0.67–0.97), whilst recent ideal CVH scores were associated with a lower 10-year risk of stroke (HR 0.80, 95%
CI 0.67–0.95) and VaD (HR 0.49, 95% CI 0.30–0.81), but not AD and all-cause dementia. These differences probably
highlight that stroke is a relatively acute sequela of poor CVH, whilst dementia is an insidious process developing over
decades. Higher recent and remote ideal CVH scores were associated with less decline in visual memory, reasoning
and verbal comprehension. Two other studies corroborate the data above that ideal CVH was associated with better
neuropsychological outcomes in multiple cognitive areas [188,190]. In addition, higher recent ideal CVH was asso-
ciated with less frontal brain atrophy but not global atrophy on MRI, whilst higher remote ideal CVH was associated
with global but not frontal atrophy (n=1,287); no association was seen between ideal CVH at either time point and
WMH volume [189].
The authors advocate promoting ideal CVH, targeting the middle-aged in particular, to protect against all forms
of vascular brain injury [189].
A large Finnish RCT [191] included 2,654 people aged 60–77 years with a CAIDE [192] score of 6 or higher
(comprising age, sex, education, systolic blood pressure, BMI, total cholesterol and physical activity [range 0–15])
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and cognition at the mean or slightly lower than expected for age. Participants were randomized to either a 2-year
multi-domain intervention (diet, exercise, cognitive training and monitoring of vascular risk) or control (general
health advice). The primary outcome was mean change in cognition (neuropsychological test battery Z-scores) at
2 years. The estimated between group difference in the change in cognitive performance per year was 0.022 (95% CI
0.002–0.042, p= 0.03) in favour of the intervention. Therefore, a multi-domain intervention can improve or at least
maintain cognition in an at-risk cohort in later life. The authors did not establish the contribution of the individual
components of the multi-domain intervention to the effect seen overall [191].
On-going and future research possibilities
The European Society of Hypertension–Chinese Hypertension League–Stroke in Hypertension Optimal Treatment
(ESH–CHL–SHOT) trial is a factorial design RCTwith two different LDL cholesterol targets and three different blood
pressure targets aiming to recruit 925 participants with hypertension and stroke or TIA within the preceding 1 to 6
months prior to randomization. Investigators are able to prescribe a statin of their choosing and cognition is assessed
using the Montreal Cognitive Assessment (MoCA) as a secondary outcome over 4 years of follow-up [193].
Unanswered questions future research should seek to address are detailed in Box 1.
Conclusion
The associations between cholesterol and SVD, stroke, cognitive impairment and subsequent dementia are complex
and as yet not fully understood. Given the ageing population, there is an urgent need to find treatments to prevent
and treat dementia. In the absence of evidence to guide clinical practice, it seems appropriate to treat those patients
with vascular risk factors that meet criteria for lipid-lowering therapy, in terms of primary and secondary prevention
of cardiovascular and cerebrovascular events, in line with current guidelines [26,194]. As we have alluded to, man-
agement of the individual patient in a holistic manner according to their own vascular risk profile is recommended.
Overall, there is no evidence to support lipid-lowering therapy in patients for the management of VaD or AD. Giving
statins in later life to prevent or treat dementia is not recommended, whilst in midlife data are lacking. Although
this paucity of randomized controlled evidence makes for challenging clinical decision making, it provides multiple
opportunities for on-going and future research.
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